Evidence map›Paper›PMID 14683633›Full record

ReviewCurrent neurology and neuroscience reports2004

Spinal muscular atrophy.

Susan T Iannaccone, Stephen A Smith, Louise R Simard

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Aminoglycoside interactions and impacts on the eukaryotic ribosome.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Spinal muscular atrophy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2008
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Susan T IannacconeDivision of Neuromuscular Disease and Neurorehabilitation, Texas Scottish Rite Hospital for Children, 2222 Welborn Street, Dallas, TX 75219, USA. susan.iannaccone@tsrh.org
Stephen A Smith
Louise R Simard
Texas Scottish Rite Hospital for Children · US

Funding

CLINICAL TRIALS FOR PEDIATRIC SPINAL MUSCULAR ATROPHYR01NS039327 · NINDS · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI IANNACCONE, SUSAN T · 2000 to 2005
$3.7M
NINDS NIH HHS R01 NS39327-03
6 · The paper itself

Abstract

Spinal muscular atrophy is a common genetic disease of the motor neuron (frequency of eight cases per 100,000 live births) with a high mortality during infancy and no known treatment. Death is caused by severe and progressive restrictive lung disease. New information regarding the nature and function of the SMN protein and the availability of new pharmacologic agents now make it possible to consider clinical trials in this disease. Rehabilitation and proper management of medical complications have improved both the quality and duration of life for children with spinal muscular atrophy.

Indexed as

AnimalsAnterior Horn CellsChildClinical Trials as TopicCyclic AMP Response Element-Binding ProteinDisease Models, AnimalHumansNerve Tissue ProteinsRNA-Binding ProteinsSMN Complex ProteinsSpinal Muscular Atrophies of ChildhoodTranscriptional ActivationTreatment OutcomeUp-RegulationCyclic AMP Response Element-Binding ProteinNerve Tissue ProteinsRNA-Binding ProteinsSMN Complex Proteins

Identifiers

PMID14683633
OpenAlexW2773945241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.